- Hybrid humoral immune response of Pacific Islanders to BNT162b2 vaccination and
   Delta/Omicron infection: a cohort study
- 3
- 4 Catherine Inizan<sup>1,12,\*</sup>, Adrien Courtot<sup>2</sup>, Chloé Sturmach<sup>3,4</sup>, Anne-Fleur Griffon<sup>1</sup>, Antoine Biron<sup>5</sup>,

5 Timothée Bruel <sup>6,7,8</sup>, Vincent Enouf<sup>3,4</sup>, Thibaut Demaneuf<sup>9,§</sup>, Sandie Munier<sup>4</sup>, Olivier Schwartz <sup>7,8</sup>, Ann-

6 Claire Gourinat<sup>5, #</sup>, Georges Médevielle<sup>2</sup>, Marc Jouan<sup>1</sup>, Sylvie van der Werf<sup>3,4</sup>, Yoann Madec<sup>10</sup>, Valérie

- 7 Albert-Dunais<sup>11</sup>, Myrielle Dupont-Rouzeyrol<sup>1</sup>.
- 8
- 9 1. Dengue and Arboviroses Research and Expertise Unit Institut Pasteur in New Caledonia Pasteur
  10 Network, 110 Bvd Joseph Wamytan, 98835 Dumbéa-sur-Mer, New Caledonia.
- 11 2. Provincial Office for Health and Social Action of the South Province (Direction Provinciale de
- 12 l'Action Sanitaire et Sociale en Province Sud), 12 rue de Verdun, 98800 Nouméa, New Caledonia
- 13 3. National Reference Center for Respiratory Viruses, Institut Pasteur, Université Paris Cité, Paris,
  14 France.
- 4. Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569,
   Paris, France
- 17 5. New Caledonia Territorial Hospital, 110 Bvd Joseph Wamytan, 98835 Dumbéa-sur-Mer, New18 Caledonia
- 19 6. Antiviral Activities of Antibodies Group, Institut Pasteur, Université Paris Cité, CNRS UMR3569,
- 20 Paris, France
- 21 7. Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France
- 22 8. Vaccine Research Institute, Créteil, France

23 9. Social and Sanitary Agency of New Caledonia (Agence Sanitaire et Sociale de Nouvelle-Calédonie),

- 24 Nouméa, New Caledonia
- 25 10. Epidemiology of Emerging Diseases, Institut Pasteur, Université de Paris, 75000 Paris, France.
- 26 11. New Caledonia Specialized Hospital, 42 rue Eschembrenner, Nouville BP 120, 98845 Nouméa, New
- 27 Caledonia.
- 28 12. Lead contact
- 29 \$: Current address: Pacific Community SPC Public Health Division B.P. D5, 98800 Nouméa, New
- 30 Caledonia

- #: Current address: New Caledonia Health Authorities (Direction des Affaires Sanitaires et Sociales de
- Nouvelle-Calédonie), 7 ave Paul Doumer, BM M2, 98849 Nouméa Cedex, New Caledonia \*Correspondence: cinizan@pasteur.nc

#### 34 Summary

#### 35 Background

Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune
 response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination
 strategies adapted to Pacific Islanders singularities.

#### **39** Methods

We evaluated the humoral immune response of 585 adults self-declaring as Melanesians, Europeans,
Polynesians or belonging to other communities to Pfizer BNT162b2 vaccine. Anti-Spike and antiNucleoprotein IgG levels, capacity to neutralize SARS-CoV-2 variants and capacity to mediate
Antibody-Dependent Cellular Cytotoxicity (ADCC) were assessed across communities at one and three
months post-second dose or one and six months post-third dose.

#### 45 Results

61.3% of the sera tested contained anti-Nucleoprotein antibodies, evidencing mostly a hybrid immunity 46 resulting from vaccination and SARS-CoV-2 infection. Anti-Spike IgG levels and capacity to mediate 47 48 Omicron neutralization and ADCC were equivalent across the four ethnic communities at one-month post-immunization, during follow-up and at six months post-third dose, regardless of the infection 49 status. Obese individuals (BMI>30 kg/m<sup>2</sup>) had significantly higher anti-Spike IgG levels at one-month 50 post-immunization (+0.26 (0.04; 0.48) AU in LuLISA assay, p value = 0.017). Odds of Omicron 51 52 neutralization at six months after the third dose decreased significantly in the 40-64 years and  $\geq$ 65 years 53 groups (OR (95% CI) 0.48 (0.24-0.90) and 0.29 (0.14-0.58) respectively, p-value = 0.003).

#### 54 Conclusions

Our study evidenced Pacific Islander's robust humoral immune response to Pfizer BNT162b2 vaccine,
which is pivotal to re-enforce vaccination deployment in a population at risk for severe COVID-19

57 (clinicaltrials.gov: NCT05135585).

#### 58 Keywords

- 59 COVID-19 vaccines; Pfizer BNT162b2; Immunity, humoral; antibodies; Pacific Island people;
- 60 neutralization; Antibody-Dependent Cell Cytotoxicity

#### **40-words summary**

Ethnicity has little impact on Pacific Islanders' hybrid humoral immune response to BNT162b2
vaccination and SARS-CoV-2 infection. Anti-Spike IgG levels, capacity to neutralize Omicron variants
and capacity to mediate Antibody-Dependent Cellular Cytotoxicity are equivalent across Pacific
communities following BNT162b2 vaccination.

#### 66 Introduction

67 Covering 8.5 million km<sup>2</sup> in a maritime area of 80 million km<sup>2</sup>, emerged Pacific territories excluding 68 Australia are populated by ≈17 million inhabitants, among which 11.6 million belong to communities 69 of Non-European Non-Asian descent <sup>1</sup>. Pacific Islanders are at risk of severe respiratory infections, 70 including influenza <sup>2</sup> and COVID-19 <sup>3</sup>. As vaccination protects from severe COVID-19 in cohorts 71 mostly composed of White people <sup>4</sup>, it is pivotal to assess whether Pacific Islanders' humoral response 72 to anti-COVID-19 vaccination is equivalent to the one of White people.

New Caledonia (NC) is a French overseas territory of ≈270,000 inhabitants in the South Pacific region,
where 41.2% self-declare as Melanesian, 24% as European, 8.3% as Polynesian and 26.5% as belonging
to other communities <sup>5</sup>.

A zero COVID policy protected NC from early SARS-CoV-2 spread. In September 2021, the first epidemic peak was caused by the Delta variant. Two larger epidemic peaks due to Omicron BA.1 and BA.4/.5 occurred in 2022 (Supplementary figure 1). Almost 80,000 infections and 314 deaths were detected <sup>6,7</sup>. Vaccination roll-out, involving almost exclusively Pfizer BNT162b2 vaccine, was initiated in January 2021. As of May 2023, 70% of the entire population had received at least one dose, 68% had received at least two doses and 38% had received a booster dose <sup>8</sup>.

Considering ethnic representation in COVID-19 vaccine trials is crucial 9. However, in Pfizer 82 83 BNT162b2 efficacy trial, the cohort included only 0.2% Native Hawaiians/other Pacific Islanders <sup>10</sup>, precluding to assess vaccine efficacy in this population. As a consequence, data on anti-SARS-CoV-2 84 immunity in vaccinated Pacific populations remain scarce. In a New Zealand cohort study, the 80 Pacific 85 people included had lower anti-SARS-COV-2 antibody titers than Europeans and Maoris 28 days after 86 two doses of BNT162b2 vaccine. However, when adjusting for the higher prevalence of diabetes in 87 Pacific people, antibody titers and variant neutralization did not differ by ethnicity <sup>11</sup>. Similarly, 88 Australian First Nations people deployed a prototypical immune response to Pfizer BNT162b2 vaccine, 89 90 with humoral and cellular responses at similar levels than Non-Indigenous people<sup>12</sup>.

Anti-Spike antibody levels, neutralization capacity and antibodies functionality, including AntibodyDependent Cellular Cytotoxicity (ADCC) <sup>13</sup>, play an important role in COVID-19 pathogenesis. ADCC
was indeed higher in hospitalized or severe patients who survived than in fatal cases <sup>13,14</sup>, suggesting its
protective role.

Adaptation of regional vaccination strategies to Pacific populations' singularities requires to evaluate 95 COVID-19 vaccines' immunogenicity and hybrid immunity upon breakthrough infection in Pacific 96 populations. The current study postulated that the hybrid humoral response to Pfizer BNT162b2 vaccine 97 98 was equivalent across the four ethnic communities in NC. We aimed to characterize Pacific Islanders' hybrid humoral response to BNT162b2 vaccine and SARS-CoV-2 infection, by evaluating anti-Spike 99 IgG levels, the neutralization capacity and the ability to mediate ADCC of sera longitudinally collected 100 in a cohort of 585 vaccinated adults from New Caledonia self-declaring as Melanesians, Polynesians, 101 102 Europeans or belonging to other communities.

#### 103 Results

104 *Hybrid humoral response was highly prevalent in the cohort.* 

This study enrolled 585 participants, among which 148 self-declared as Melanesians, 189 as Europeans, 82 as Polynesians and 166 as belonging to other communities. Sixty-eight participants were sampled at one month post-second dose (D2.1) and 56 participants were sampled at three months post-second dose (D2.3), of whom 50 participants were sampled at both timepoints (Figure 1). A total of 237 participants were sampled at 1 month post-third dose (D3.1) and 488 participants were sampled at 6 months postthird dose (D3.6), of whom 214 participants were sampled at both timepoints (Figure 1). Overall, 849 blood samples were collected and analyzed. All samples contained anti-Spike IgG.

112 Eighty-five participants (14.5%) reported a positive COVID-19 test at one of the sampling timepoints.

113 Participants exhibiting anti-Nucleocapsid antibodies, sign of a previous or current infection, at D2.1,

114 D2.3, D3.1 and D3.6, were 47 (69.1%), 43 (76.8%), 150 (63.3%) and 280 (57.4%), respectively (Figure

- 115 2). In the 18 and 113 participants with anti-Nucleocapsid antibodies and followed up between D2.1/D2.3
- or D3.1/D3.6, 9 re-infections and 9 new infections despite immunization (breakthrough infections) and

117 73 re-infections and 40 breakthrough infections were identified after the second and the third dose,118 respectively. Subsequent multivariate regression and logistic models were adjusted for infection status.

119 *Humoral response at one-month post-vaccination is equivalent across ethnic communities.* 

Among the 305 participants sampled at one-month post-immunization (68 and 237 sampled at D2.1 and D3.1, respectively), ethnicity was distributed as follows: 55 Melanesians, 79 Europeans, 55 Polynesians and 116 participants belonging to other communities (Supplementary Table 1). The proportion of women was 54.6%. Age of participants ranged from 19 to 82 years, with European participants significantly older (p=0.002, Kruskal-Wallis). Previous infection was significantly less frequent in Europeans (p=0.005, Khi-2 test). BMI was significantly lower in Europeans (p<0.001, Kruskal-Wallis test).

Levels of anti-Spike IgG (anti-S IgG, p < 0.001, Table 1 and Supplementary Table 2) and the ability to neutralize Omicron (p < 0.001, Supplementary Table 2) were significantly higher one month after the third dose than after the second dose, irrespective of the infection status (Figure 3a). Previous SARS-CoV-2 infection was significantly associated with higher titers after the third dose (p < 0.001, Figure 3A). After the second dose, Omicron neutralization was significantly more frequent in those with a previous infection (p=0.004, Table 2).

Linear regression confirmed that number of doses and infection status were independently and significantly associated with higher anti-S IgG titers (adjusted effect +1.27, 95% CI (1.06; 1.49), p<0.001 and + 0.38, 95% CI (0.19; 0.56), p<0.001, respectively, Table 1). Obesity was associated with significantly higher anti-S IgG titers (adjusted effect +0.24, 95% CI (+0.03; +0.46), p=0.008). Male gender was significantly associated with lower anti-S IgG titers (adjusted effect -0.19, 95% CI (-0.37; -0.01), p=0.036). Importantly, ethnic community was not associated with anti-S IgG titers (p=0.34) (Figure 3B).

In a ROC curve analysis, a threshold of 5.737 AU maximized the proportion of subjects exhibiting anti-S
IgG levels above the threshold who were able to neutralize Omicron (75% sensitivity) while minimizing

8

the proportion of participants below the threshold able to neutralize Omicron (95% specificity)(Supplementary figure 2).

144 Pseudovirus neutralization assays showed that almost all individuals sampled one month after 145 immunization were able to neutralize the vaccine strain Wuhan and the Delta variant (Figure 3C). The 146 ability to neutralize Omicron BA.1 and/or BA.4/5 however significantly differed by number of doses 147 (Figure 3C), with 19.1% and 97.9% participants neutralizing Omicron after the second and third dose, respectively (Supplementary Table 2). In analyses stratified by immunization dose, only anti-S IgG 148 149 levels were significantly associated with neutralization (OR (95% CI): 88.33 (15.79-805.92), p<0.001 at D2.1, and 12.00 (1.73-237.30), p=0.028 at D3.1 Table 2). After two immunizations, only anti-S IgG 150 levels remained significantly associated with Omicron neutralization (p < 0.001). After three 151 immunizations, in univariate analysis, no factor other than anti-S IgG levels (p=0.028) was associated 152 153 with Omicron neutralization (all p-values>0.20). Importantly, ethnic community was not associated with different odds to neutralize Omicron (p=0.59 and p=0.60 at D2.1 and D3.1, respectively).154

All participants but 7 were able to activate CD16 following exposure to SARS-CoV-2 Spike, reflecting a capacity to mediate ADCC. Multivariate linear regression showed that anti-S IgG levels  $\geq$  5.737 AU and male gender were independently associated with higher ADCC activation (+0.61 (0.29; 0.94), p<0.001 and +0.47 (0.14; 0.79), p=0.005, respectively, Table 3). Importantly, ethnic community was not associated with the capacity to mediate ADCC (p=0.069 in multivariate linear regression).

160 Humoral response to SARS-CoV-2 over 6 months post-third dose is similar across ethnic communities

Among the 214 participants who were evaluated at both D3.1 and D3.6, 29 self-declared as Melanesians, 57 as Europeans, 42 as Polynesians and 86 as belonging to other communities (Supplementary table 3). Europeans were significantly older (p=0.022, Kruskal-Wallis test), showed less frequently signs of previous infection (p=0.059, Khi<sup>2</sup> test) and had lower BMI (p<0.001, Kruskal-Wallis test) (Supplementary table 3). Between D3.1 and D3.6, anti-S IgG levels decreased in median (IQR) by 1.67 AU (0.63; 2.59) (Supplementary table 3). The multivariate linear regression model showed that in participants never infected and with anti-S IgG levels <5.737 at D3.1, the anti-S IgG levels decreased 168 (in mean (95% CI)) by 1.98 AU (1.56; 2.39) between D3.1 and D3.6 (Supplementary table 4). In 169 participants with anti-S IgG levels >5.737 at D3.1, the decrease was significantly steeper (-2.52 AU (-170 2.90; -2.14), p<0.001). In participants with breakthrough infection, anti-S IgG levels remained stable.

Two hundred and nine participants out of 214 showed the ability to neutralize Omicron at D3.1 171 (Supplementary table 3). Of them, 35 (16.7%) had lost this ability by D3.6 (Supplementary table 3). 172 173 Multivariate logistic regression evidenced that previously infected individuals had significantly lower odds to lose Omicron neutralization capacity (adjusted OR (95% CI): 0.20 (0.07-0.53), 0.06 (0.01-0.24) 174 175 and 0.04 (0.01-0.15) for previous infection, breakthrough infection and reinfection, respectively; p < 0.001, Supplementary table 5). Males had higher odds to lose this ability (adjusted OR (95% CI): 176 2.64 (1.12-6.56); p=0.030, Supplementary table 5). Compared to the participants aged<40 years, those 177 aged 40-64 years and  $\geq$ 65 years had higher odds to lose Omicron neutralization capacity (adjusted OR 178 179 (95% CI): 5.74 (1.87-22.19) and 7.89 (2.02-36.13), respectively; p=0.008, Supplementary table 5). 180 Importantly, ethnic community was not associated with the loss of Omicron neutralization capacity 181 between D3.1 and D3.6 (Supplementary table 5).

ADCC activation remained stable between D3.1 and D3.6 (median (95% CI) difference (+0.20 AU (-182 0.41; 0.61)). The multivariate linear regression model showed that the capacity to mediate ADCC in 183 female participants who were never infected remained stable in time (mean (95% CI) progression -0.16 184 185 (-0.53; 0.21)) (Supplementary table 6). In participants with breakthrough infection between D3.1 and D3.6, the capacity to mediate ADCC significantly increased between D3.1 and D3.6 (mean (95% CI) 186 progression of +0.51 AU (0.13; 0.88), p=0.0087). In male participants, the capacity to mediate ADCC 187 significantly decreased between D3.1 and D3.6 (mean (95% CI) progression of -0.47 AU (-0.85; -0.08), 188 p < 0.018)). Importantly, the ethnic community was not associated with an evolution in the capacity to 189 190 mediate ADCC (p=0.80 in univariate linear regression).

191 Humoral response to SARS-CoV-2 at 6 months post-third dose is similar across ethnic communities

Among the 488 participants sampled at D3.6, 119 self-declared as Melanesians, 166 as Europeans, 68

as Polynesians and 135 belonged to other communities (Supplementary table 7). Europeans were older,

had lower BMIs, exhibited signs of previous infection less frequently and were less able to neutralize Omicron. Past infection was significantly more frequent in Melanesians and "other communities"  $(p<0.001, \text{Khi}^2 \text{ test})$ . Previous infection was significantly associated with higher anti-S IgG levels (crude effect +1.16, 95% CI (0.91; 1.41), p<0.001, Supplementary table 8). Melanesians and other communities showed higher anti-S IgG levels in univariate analysis. In multivariate analysis, only the infection status remained significantly associated with higher anti-S IgG levels.

200 Of these participants, 362 (74.2%) showed ability to neutralize Omicron. In the multivariate model, 201 previous infection and higher anti-S IgG levels were independently associated with higher odds of neutralization at D3.6 (adjusted OR (95% CI): 4.04 (2.54-6.50), p<0.001 and 51.64 (11.00-922.94), 202 p < 0.001, respectively; Supplementary table 9). Conversely, males had lower odds to neutralize Omicron 203 (adjusted OR (95% CI): 0.61 (0.38-0.97), p=0.024). As compared to participants aged <45 years, those 204 205 aged 40-64 years and ≥65 years also had lower odds to neutralize Omicron (adjusted OR (95% CI): 0.48 (0.24-0.90) and 0.29 (0.14-0.57), p=0.0024). Capacity to neutralize Omicron at D3.6 was independent 206 207 of the ethnic community.

#### 208 Discussion

This study found that Europeans, Melanesians, Polynesians and other communities had equivalent anti-S IgG titers and capacity to neutralize Omicron and mediate ADCC following Pfizer BNT162b2 vaccination and SARS-CoV-2 infection. They showed a similar maintenance of their hybrid humoral response 6 months after immunization. Melanesians' and other communities' higher anti-S IgG levels at D3.6 were associated with more frequent infections, probably resulting from different lifestyles across communities in NC, which may favor transmission <sup>2</sup>.

Population genetic studies have revealed that ancient admixture between humans and Denisovans left traces in present-day Pacific Islanders' genomes <sup>15</sup>, introducing genetic variants almost exclusively related to immune response regulation <sup>16</sup>. How genetic traits from archaic humans contribute to phenotypic differences between contemporary individuals, especially relating to their immune response, is poorly known. We showed here that Pacific Islanders' genetic uniqueness did not translate in differential hybrid humoral response to SARS-CoV-2. Although some genetic variants have been
associated with antigen-specific IgG levels <sup>17</sup>, neither their presence in Pacific populations nor their
impact on anti-SARS-CoV-2 IgG levels have been explored. Our results are consistent with robust
antibody response and neutralization after two doses of BNT162b2 vaccine in a cohort comprising 80
Pacific people <sup>11</sup>. Such efficient hybrid humoral response of Pacific Islanders highlights the importance
of pursuing vaccination efforts in this population at risk for severe COVID-19.

We found that hybrid immunity resulting from BNT162b2 vaccination and SARS-CoV-2 infection was 226 227 highly prevalent in our cohort. Due to COVID-19 epidemiology in NC (Supplementary figure 1), infected participants sampled at D2.1 or later timepoints were likely infected by the Delta variant, or 228 either by the Delta or Omicron variants, respectively. In our study, hybrid immunity translated in a 229 robust anti-S IgG secretion with efficient Omicron neutralization capacity compared to non-infected 230 231 vaccinees, in Pacific Islanders as well. A third dose of BNT162b2 vaccine resulted in Omicron 232 neutralization in almost all participants, independently from a previous infection. Consistently, hybrid immunity was shown to boost antibody levels and poly-functionality regardless of the sequence of 233 natural infection and vaccination <sup>18</sup>, resulting in a significant and lasting protection against Omicron 234 infection <sup>19</sup>. Recall of memory B cells generated after the original infection contributes to this increase 235 in variant-neutralizing antibodies after vaccination <sup>20</sup>. Enhancement of variant-neutralizing capacity in 236 237 infected vaccinees supports the relevance to vaccinate Pacific Islanders, who exhibit higher COVID-19 238 seroprevalences (Huet et al., in prep).

239 We observed that self-declared males had lower anti-S IgG titers at one month after immunization, 240 which did not translate in differential neutralization capacity. Sex did not affect antibody decline between D3.1 and D3.6. However, the loss of Omicron neutralization capacity between D3.1 and D3.6 241 242 was more likely in males, resulting in lower odds of Omicron neutralization at D3.6. Furthermore, the 243 capacity to mediate ADCC was enhanced at one-month post-immunization but decreased more rapidly 244 in males. Consistently, males were shown to secrete lower antibody levels after two doses of BNT162b2 <sup>21</sup>. However, anti-S IgG levels were shown to decline faster in males after infection <sup>22</sup>. Higher antibody 245 titers in females were observed for several vaccines <sup>23,24</sup>, suggesting a differential effective vaccine dose 246

according to sex. Overall, while several studies demonstrated an impact of sex on the humoral response
 <sup>22,25</sup>, the underlying mechanisms remain poorly characterized.

249 In addition, we found that age did not affect antibody decline between D3.1 and D3.6, probably due to 250 significantly lower anti-S IgG levels in the  $\geq$ 40 years age groups at one-month after immunization. Consistently, older individuals exhibit lower antibody levels after two doses of BNT162b2, with similar 251 decline across ages <sup>21</sup>. Individuals aged  $\geq$ 40 years had lower odds of Omicron neutralization at D3.6. 252 Age might therefore impact humoral response polyfunctionality. SARS-CoV-2 vaccination's outcome 253 correlates with signs of immunosenescence <sup>26</sup>, probably contributing to this loss of Omicron 254 neutralization in older individuals. This highlights the importance to offer booster doses to the elderly 255 to prevent the loss of Omicron neutralization capacity, in Pacific Islanders as well. 256

In this study, higher BMIs were associated with higher anti-S IgG levels at one-month postimmunization, in turn associated with higher odds of Omicron neutralization. However, impact of BMI on humoral immunity to natural infection and BNT162b2 vaccination is controversial <sup>27-29</sup>. Nonetheless, this result emphasizes the benefits of vaccinating obese individuals, who are overrepresented among Pacific Islanders.

262 The current study suffers limitations: first, the high rate of SARS-CoV-2 infections prevented to assess 263 ethnicity's impact on the humoral response to vaccination alone. Nonetheless, infection status was taken into consideration in multivariate models. As SARS-CoV-2 immunity worldwide is predominantly 264 hybrid, characterization of a population's immunity, independently of its infection status, is highly 265 relevant to adapt Public Health strategies. Second, the current study relied on self-declared ethnicity, 266 267 without genetic determination of ancestry. Although mixed marriages are common, participants had the opportunity to identify as "Other communities" including metis. Self-declared ethnicity was thus an 268 appropriate surrogate to genetically-determined ancestry. Finally, the sample size was not reached, 269 hindering to ascertain response equivalence between communities. However, the lack of community 270 271 effect, despite different prevalence of obesity, strongly suggests that SARS-CoV-2 hybrid humoral 272 response does not differ between communities.

Overall, by investigating the hybrid immune response of Pacific Islanders to SARS-CoV-2, our study
sheds light on the health of a population neglected in human studies, opening the door to considering
Pacific Islanders' uniqueness in Health studies.

276 Methods

277 *Ethics* 

The current study was conducted in compliance with the Declaration of Helsinki principles and recorded
on clinicaltrials.gov (ID: NCT05135585). Samples came from participants who gave their written
informed consent as part of this study. This study was approved by the "Comité de Protection des
Personnes Ile-de-France III" (n° ID-RCB 2021-A01949-32, CPP n° 4003-I, November 9th 2021,
Am8898-1-4003 January 17th, 2022, Am9503-2-4003 April, 4th 2022 and Am9508-3-4003 June 21<sup>st</sup>,
2022) and by the Consultative Ethics Committee of New Caledonia.

#### 284 Cohort and study design

285 Enrolment took place in immunization centres in the South Province of NC, where adults ( $\geq 18$  years) 286 who received the Pfizer BNT162b2 vaccine were approached. Initially, individuals who received their second dose were approached. When the 3<sup>rd</sup> dose was rolled out, participants who received their 3<sup>rd</sup> dose 287 were approached. In a third phase, individuals having received a 3<sup>rd</sup> dose within the last 6 months were 288 289 also approached (Figure 1). Documented SARS-CoV-2 infection (serologic, PCR or antigenic testing) 290 was an exclusion criterion. Pregnant or breast-feeding women, immunosuppressed individuals, 291 individuals unable to answer the questionnaire and those under protective measures were excluded. Sample size calculation for this equivalence study was based on a power of 85% to detect changes of 292 293 more than 5% in the fraction of participants developing anti-S IgG in response to Pfizer BNT162b2 vaccination, with an alpha risk of 5%, resulting in the requirement to enroll 141 participants in each 294 community. 295

Clinico-epidemiological data were recorded at enrolment in RedCap (Vanderbilt University, USA). A
home visit by a qualified nurse was arranged one month (+/- 10 days) after the second or third dose and
either 3 months after the second dose or 6 months after the third dose. Upon these visits, a 4-mL venous

blood sample was collected. Not all participants enrolled in the study participated to the follow-up. Sera
were separated from blood samples by centrifugation and stored at -20°C until subsequent analyses.

301 *Cells and reagents* 

HEK 293T-hACE2 cells were cultured at 37°C under 5% CO<sub>2</sub> in complete culture medium composed
of Dulbecco's modified Eagle's medium (DMEM, Gibco) complemented with 10% fetal calf serum
(Gibco), 1% penicillin/streptomycin (Gibco) and 2mM L-Glutamine (Gibco). Cells were detached and
resuspended using 0.05% Trypsin-EDTA (Gibco).

306 Recombinant SARS-CoV-2 Wuhan Spike or Nucleocapsid proteins were kindly provided by S. Petres

307 <sup>30</sup>. Secondary lama antibodies VHH anti-human IgG Fc coupled to NanoKAZ were kindly provided by

308 Thierry Rose. Z108 NanoKAZ substrate was kindly provided by Yves Janin.

#### 309 *Pseudotyped viruses*

310 Pseudotyped lentiviral vectors enveloped with the Spike protein from Wuhan, Delta, Omicron BA.1 or Omicron BA.4/5 SARS-CoV-2 variants were produced as previously described <sup>29</sup>. Briefly, HEK 293T 311 312 cells were co-transfected with a packaging plasmid Gag-Pol (NR-52517, BEI Resources), Helper Plasmids Tat1b (NR-52518, BEI Resources) and Rev1b (NR-52519, BEI Resources), a transfer plasmid 313 314 carrying the gene encoding the Spike Glycoprotein of Wuhan-Hu-1 (GenBank: NC 045512, plasmid 315 NR-52514, BEI Resources), Delta, Omicron BA.1 or Omicron BA.4/5 SARS-CoV-2 variants and a 316 Lentiviral Backbone carrying a luciferase reporter gene Luc2 and a ZsGreen gene (pHAGE-CMV-Luc2-IRES-ZsGreen-W, NR-52516, BEI Resources). At 48h post-transfection, supernatants were collected, 317 clarified by centrifugation and frozen at -80°C. 318

319 LuLISA experiments

Sera were decomplemented at 56°C for 35 min. White 384-well tissue-culture plates (Greiner Bio-one)
were coated with recombinant SARS-CoV-2 Wuhan Spike or Nucleocapsid proteins at 1 μg/mL in

322 Phosphate Buffer Saline (PBS, Gibco) through 4h incubation at room temperature. Plates were washed

323 with PBS containing 0.1% Tween (Tween @20, Sigma-Aldrich) using a plate washer Zoom microplate

Washer (Titertek Berthold). Sera were diluted 1/200 in PBS containing 1% skimmed milk and 0.1% 324 325 Tween using a Tecan Fluent 780 and incubated in duplicate for 2h in Spike- or Nucleoprotein-coated plates. Plates were washed with PBS containing 0.1% Tween. Secondary VHH lama antibodies anti-326 327 human IgG Fc coupled to NanoKAZ were diluted at 20 ng/mL in PBS containing 1% skimmed milk and 0.1% Tween and added to the plates. After 1h30 incubation, Z108 NanoKAZ substrate was added 328 to the plates at 6 µg/mL. Bioluminescence was measured using Mithras<sup>2</sup> LB943 Multimode reader 329 330 luminometer (Berthold technologies). Presence of anti-Spike IgG above the 0.25 AU was indicative of 331 an immunization against SARS-CoV-2. Past COVID-19 infection was determined by the presence of anti-Nucleocapsid antibodies above 0.3 AU. 332

#### 333 Pseudovirus neutralization assay

Decomplemented sera (56°C for 35 min) were diluted 1/40 and coincubated with pseudotyped lentiviral 334 vectors at room temperature for 50 min in complete culture medium prepared using DMEM without 335 336 phenol red (Gibco). The mixture was then plated in white 96-well tissue-culture plates (Greiner Bio-One). A suspension of 20,000 HEK 293T-hACE2 cells was added in each well. Single-cell suspensions 337 were prepared in Dulbecco's Phosphate Buffer Saline (DPBS) containing 0.1% EDTA (Promega) to 338 preserve hACE2 protein integrity. Serum-lentivirus mixes and addition of the cells were all performed 339 340 using a Tecan Fluent 780. After 72h, Bright-Glo Luciferase substrate (Promega) was added to the cells (1:1). Bioluminescence was measured using Centro XS3 LB 960 or Mithras<sup>2</sup> LB943 Multimode reader 341 luminometers (Berthold technologies). 342

A set of negative sera was used to determine the threshold as the average luminescence level of thesenegative sera minus 3 standard deviations.

The percentage of neutralization was expressed as  $(1 - (\text{measured value/threshold})) \ge 100$ . The ability to neutralize Omicron variant was defined in pseudovirus neutralization assays as  $\ge 90\%$  neutralization of Omicron BA.1 and/or Omicron BA.4/5 pseudoviruses by a 1/40 dilution of the serum (ie neutralization titer >40).

349 Antibody-Dependent Cellular Cytotoxicity (ADCC)

350 CD16 activation was quantified as a surrogate assay to measure sera's capacity to mediate ADCC. 351 ADCC was quantified using the ADCC Reporter Bioassay (Promega) and 293T cells stably expressing 352 the Wuhan spike. Briefly, spike-expressing cells  $(3 \times 10^4 \text{ per well})$  were co-cultured with Jurkat-CD16-353 NFAT-rLuc cells ( $3 \times 10^4$  per well) in presence or absence of sera diluted 1/30. Luciferase was measured after 18h of incubation using an EnSpire plate reader (PerkinElmer). ADCC was measured as the fold 354 induction of Luciferase activity compared to the "no serum" condition. For each serum, the control 355 356 condition (cells transfected with an empty plasmid) was subtracted to account for inter-individual 357 variations of the background. We previously reported correlations between the ADCC Reporter 358 Bioassay titers and an ADCC assay based on primary NK cells and cells infected with an authentic virus <sup>13</sup>. ADCC analyses were conducted on all samples collected at one-month post-immunization but two 359 and on all corresponding follow-up samples collected 6 months after the 3<sup>rd</sup> dose. 360

#### 361 *Statistical analyses*

Quantitative variables were characterized by the median, inter-quartile range (IQR) and range. Age was
categorized into three groups: 18-39, 40-64 and ≥65 years. Participants with a Body Mass Index (BMI)
strictly below 18.5 kg/m<sup>2</sup>, comprised between 18.5 and 24.9 kg/m<sup>2</sup>, comprised between 25 and 29.9
kg/m<sup>2</sup> or over 30 kg/m<sup>2</sup> were considered as underweight, normal weight, overweighted or obese,
respectively.

367 Proportions were compared using Chi-2 test. Continuous variables were compared using Kruskal-Wallis test. The effect of immunization dose, infection status, self-declared gender, age, BMI category, 368 presence of comorbidities and self-declared ethnicity on the levels of anti-Spike antibodies and CD16 369 370 activation was investigated using linear regression models. Their effect on Omicron neutralization 371 capacity was investigated using logistic regression models. In all analyses, factors associated with the outcome with a *p*-value <0.20 in univariate analyses were considered in the multivariate model. Then, 372 a backward stepwise procedure was used to identify factors that remained independently associated with 373 374 the outcome. A *p*-value < 0.05 was considered significant. All statistical analyses were performed using R software (version R 4.2.1 GUI 1.79 High Sierra build (8095)). 375

376 Notes

#### 377 *Author contributions*

CI, MDR and VAD conceived the study. CI and MDR led the applications for funding with input from 378 379 AC, GM, MJ and VAD. Consent and questionnaire tools were designed by CI and MDR. Inclusions were implemented by CI, AC, AFG, GM, VAD and MDR. Samples were collected by home-visiting 380 nurses and handled by AB, ACG and AFG. CI, CS, AB, TB, VE, SM, OS and SW performed the 381 382 experimentations. CI, AC and TD implemented the statistical analyses under the supervision from YM. CI wrote the scientific manuscript with input from YM, MDR and all authors. All authors have had the 383 384 opportunity to access the underlying data used in this study. All authors reviewed the manuscript and 385 approved the final version prior to submission.

#### 386 Financial support

This study received financial support from the ANRS | Emerging infectious diseases, the Pasteur Network COVID-19 funding, the Institut Pasteur in New Caledonia, the Specialized Hospital from New Caledonia, the Provincial Office for Health and Social Action in the South Province in New Caledonia (DPASS-Sud) and the Regional Hospital Federation in the South Pacific (FHF).

#### 391 Acknowledgements

We would like to thank all the participants to the COVCAL study. This study has been labeled as a 392 National Research Priority by the National Orientation Committee for Therapeutic Trials and other 393 394 researches on COVID-19 (CAPNET). The investigators would like to acknowledge ANRS | Emerging 395 infectious diseases for its scientific support and funding, the French Ministry of Health and Prevention and the French Ministry of Higher Education, Research and Innovation for their funding and support. 396 397 We warmly thank the Clinical Research Department of the Centre for Translational Research at Institut 398 Pasteur in Paris for their support in ethic procedures. The authors would also like to thank Priscillia 399 Piersanti, Aurore Martini, Sabine Crescentini, Dr Christophe Assié and Dr Johanna Read along with 400 home-visiting nurses and personnel from Medical Centers for their support in the investigation, 401 Stéphane Petres and the Plateforme Technologique de Production et Purification de Protéines

- 402 Recombinantes at Institut Pasteur for the production of the N and S proteins used in the LuLISA assays,
- 403 Faustine Amara, Margot Penru, Yannis Rahou and Lou-Léna Vrignaud for technical support and Dr
- 404 Etienne Simon-Lorière and Pr John Aaskov for insightful discussions.
- 405 *Declaration of interests*
- 406 All authors declare no competing interests.
- 407 *Data sharing*
- 408 Further information and requests for reagents and resources should be directed to and will be fulfilled
- 409 by the corresponding author, Catherine Inizan (cinizan@pasteur.nc).

#### 410 Figures and Figure Legends



#### 411

Figure 1

## Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagrams of the second- and third-dose cohorts. A. The second dose cohort is composed of 126 pre-included participants, among which 68 were sampled one month after their second dose (purple square). B. The third-dose cohort is composed of 554 pre-included participants, among which 237 were sampled one month after their third dose (purple square), 214 were followed-up at one and six months after their third dose (bold frames) and 488 were sampled at 6 months after their third dose (blue square).

418

20

Distribution of the 849 samples





Figure 2

Figure 2. Description of the sample set. The 849 samples are divided into anti-N IgG (IgN) negative
samples coming from vaccinated participants with no traces of previous infection (violet), and anti-N
IgG positive samples coming from infected participants (red), breakthrough infections between one and
three months post-second dose (brown), breakthrough infections between one and six months post-third
dose (green) or reinfected participants (blue).



#### A. Magnitude of the humoral response one month after immunization

B. Magnitude of the humoral response across communities one month after immunization









426 Figure 3. Measure of anti-S IgG levels and neutralization capacity. A. Concentrations in anti-S IgG in samples collected one month after the second dose from previously infected participants (D2.1 427 428 infected, red), one month after the second dose from previously non-infected participants (D2.1 non 429 infected, green), one month after the third dose from previously infected participants (D3.1 infected, blue) and one month after the third dose from previously non-infected participants (D3.1 non infected, 430 purple). **B.** Concentrations in anti-S IgG in samples collected from self-declared Melanesian (dark blue), 431 432 European (light blue), Polynesian (light green) participants or from participants self-declaring as 433 belonging to other communities (dark green) one month after immunization. C. Heatmap of the neutralization capacity against SARS-CoV-2 variants Wuhan, Delta, Omicron BA.1 and Omicron 434 BA.4/5 one month after the second dose in previously non-infected participants (D2.1 non infected, 435 436 green), one month after the second dose in previously infected participants (D2.1 infected, red), one month after the third dose in previously non-infected participants (D3.1 non infected, violet) and one 437 438 month after the third dose in previously infected participants (D3.1 infected, blue). Gradient between dark blue and yellow denotes increasing neutralization capacity from 0% to 100% of 1/40 diluted sera. 439 440 Each line represents one participant.

#### 441 Tables

## Table 1. Factors associated with anti-S IgG levels one month after immunization (linear regression)

	N=305	Crude effect (95% CI)	<i>p</i> value	Adjusted effect (95% CI)	<i>p</i> value
Timepoint			<0.001		<0.001
Post 2 <sup>nd</sup> dose	68	Reference		Reference	
Post 3 <sup>rd</sup> dose	237	+1.24 (1.02; 1.46)		+1.27 (1.06; 1.49)	
Infected			0.004		<0.001
No	108	Reference		Reference	
Yes	197	+0.33 (0.11; 0.56)		+0.38 (0.19; 0.56)	
Gender <sup>a</sup>			0.051		0.036
Male	138	-0.18 (-0.36; 0.001)		-0.19 (-0.37; -0.01)	
Female	167	Reference		Reference	
Age (years) <sup>a</sup>			0.046		
18-39	130	Reference			
40-64	133	-0.14 (-0.34; 0.06)			
≥65	42	-0.35 (-0.63; -0.06)			
<b>Comorbidities</b> <sup>a</sup>			0.51		
No	173	Reference			
Yes	132	-0.06 (-0.25; 0.12)			
BMI <sup>a</sup>			0.017		0.008
Underweight	9	-0.26 (-0.80; 0.29)		-0.48 (-1.05; 0.10)	
Normal	93	Reference		Reference	
Overweight	90	-0.04 (-0.27; 0.19)		+0.05 (-0.28; 0.18)	
Obese	113	+0.26 (0.04; 0.48)		+0.24 (0.03; 0.46)	
Community <sup>a</sup>			0.17		
European	79	Reference			
Melanesian	55	+0.02 (-0.26; 0.30)			
Polynesian	55	+0.24 (-0.04; 0.52)			
Other	116	+0.20 (-0.03; 0.44)			

444 *aThe univariate analysis is adjusted for timepoint and infection status.* 

445 *CI: confidence interval; BMI: body mass index.* 

446 BMI classes: Underweight =  $BMI < 18.5 \text{ kg/m}^2$ , Normal weight =  $BMI \in [18.5, 25[\text{ kg/m}^2, Overweight])$ 

447 =  $BMI \ \epsilon \ [25, \ 30[ \ kg/m^2, \ Obese = BMI \ge 30 \ kg/m^2]$ 

448 Statistically significant associations (p < 0.05) with anti-S IgG levels are shown in bold.

Table 2. Factors associated with the ability to neutralize Omicron BA.1 and/or BA.4-5 one
 month after the second and third dose (logistic regression)

One month after the second dose					
	N=68	Neutralisation, n (%)	Crude OR (95% CI)	<i>p</i> value	
Infected <sup>a</sup>				0.004	
No	21	0 (0)	1		
Yes	47	13 (27.7)	16.83 (2.04-2.19)		
Level of anti-S IgG		- ()		<0.001	
<pre>// 10 10 10 10 10 10 10 10 10 10 10 10 10</pre>	56	3(54)	1	0.001	
> 5 737 AU	12	10(833)	<sup>1</sup> 88 33 (15 70_805 02)		
<u>23.137 AU</u>	12	10 (03.5)	00.55 (15.77-005.72)	0.60	
Gender	21	5(1(1))		0.00	
Male	31	5 (10.1)	0.70 (0.19-2.36)		
Female	37	8 (21.6)			
Age (years) <sup>a</sup>				0.69	
18-39	42	9 (21.4)	1		
40-64	20	4 (20.0)	0.96 (0.25-3.30)		
≥65	6	0 (0)	0.27 (0.00-2.67)		
Comorbidities				0.60	
No	38	8 (21.1)	1		
Yes	30	5 (16.7)	0.75 (0.20-2.54)		
BMI				0.14	
Normal weight	20	2 (10)	1		
Overweight	20	2(10) 3(130)	1 35 (0 20 11 14)		
Overweight	25	3(13.0) 8(22)	1.33(0.20-11.14) 1.24(0.00, 20.81)		
Commente	23	8 (32)	4.24 (0.90-30.81)	0.50	
Community	10	2 (10.0)	1	0.59	
European	16	3 (18.8)			
Melanesian	22	3 (13.6)	0.68 (0.11-4.20)		
Polynesian	9	1 (11.1)	0.54 (0.02-5.11)		
Other	21	6 (28.6)	1.73 (0.38-9.54)		
One month after the third d	ose				
	N=237	Neutralisation, n (%)	Crude OR (95% CI)	<i>p</i> value	
Infected				0.30	
No	87	84 (96.6)	1		
Yes	150	148 (98.7)	2.64 (0.43-20.36)		
Level of anti-S IgG				0.028	
<5 737 AT	62	58 (93 5)	1		
>5.737 AU	175	174(994)	12 00 (1 73_237 30)		
<u> </u>	175	1/4 (99.4)	12.00 (1.75-257.50)	0.50	
	120	129 (09 5)		0.50	
Iviale	150	120 (90.3)	(0.34 (0.07-3.33))		
Female	10/	104 (97.2)	1		
Age (years) <sup>a</sup>				0.40	
18-39	88	88 (100)			
40-64	113	109 (96.5)	0.14 (0.00-1.32)		
≥65	36	35 (97.2)	0.13 (0.00-2.57)		
Comorbidities				0.40	
No	135	133 (98.5)	1		
Yes	102	99 (97.1)	0.50 (0.06-3.05)		
BMI				0.32	
Underweight	8	7 (87.5)	0.19 (0.02-4.49)		
Normal weight	74	72 (97.3)	1		
Overweight	67	66 (98 5)	1 83 (0 17-40 00)		
	88	87 (98 9)	2 42 (0 23-52 63)		
Communitat	00		2.72 (0.23-32.03)	0.60	
Community"				0.00	

\_

European	63	61 (96.8)	1	
Melanesian	33	33 (100)	2.72 (0.21-379.95)	
Polynesian	46	44 (95.7)	0.72 (0.11-4.85)	
Other	95	94 (98.9)	2.56 (0.33-28.48)	

CI: confidence interval; BMI: body mass index, OR: Odds Ratio. 

<sup>a</sup>Logistic regression with Firth's correction.

BMI classes: Underweight = BMI<18.5 kg/m<sup>2</sup>, Normal weight = BMI  $\epsilon$  [18.5, 25[ kg/m<sup>2</sup>, Overweight = BMI  $\epsilon$  [25, 30[ kg/m<sup>2</sup>, Obese = BMI  $\geq$ 30 kg/m<sup>2</sup> 

Statistically significant associations (p < 0.05) with the ability to neutralize Omicron BA.1 and/or

BA.4-5 are shown in bold. 

Table 3. Factors associated with the level of ADCC (CD16 activation) one month after 

59	immunization	(Linear	regression)	)
----	--------------	---------	-------------	---

	n=303	Crude effect (95%	p	Adjusted effect (95%	<i>p</i> value
		CI)	value	CI)	
Timepoint			0.10		
Post 2 <sup>nd</sup> dose	66	Reference			
Post 3 <sup>rd</sup> dose	237	+0.33 (-0.06; 0.73)			
Infected			0.30		
No	108	Reference			
Yes	195	+0.18 (-0.16; 0.53)			
Level of anti-S IgG			<0.001		<0.001
<b>&lt;5.737 AU</b>	117	Reference		Reference	
≥ 5.737 AU	186	+0.58 (0.25; 0.92)		+0.61 (0.29; 0.94)	
Gender			0.010		0.005
Male	136	+0.43 (0.10; 0.76)		+0.47 (0.14; 0.79)	
Female	167	Reference		Reference	
Age (years)			0.48		
18-39	129	Reference			
40-64	132	0.13 (-0.22; 0.48)			
≥65	42	-0.17 (-0.68; 0.34)			
Comorbidities			0.60		
No	172	Reference			
Yes	131	-0.10 (-0.43; 0.23)			
BMI			0.25		
Underweight	8	-1.06 (-2.11; -0.01)			
Normal	94	Reference			
Overweight	89	-0.07 (-0.49; 0.35)			
Obese	113	-0.14 (-0.54; 0.26)			
Community			0.05		
European	78	Reference			
Melanesian	54	-0.71 (-1.21; -0.20)			
Polynesian	55	-0.36 (-0.86; 0.14)			
Other	116	-0.35 (-0.76; 0.07)			

*CI: confidence interval; BMI: body mass index.* 

BMI classes: Underweight =  $BMI < 18.5 \text{ kg/m}^2$ , Normal weight =  $BMI \in [18.5, 25] \text{ kg/m}^2$ , Overweight 

= BMI  $\epsilon$  [25, 30[ kg/m<sup>2</sup>, Obese = BMI  $\geq$  30 kg/m 

Statistically significant associations (p < 0.05) with ADCC levels are shown in bold. 

#### 467 Supplementary information titles and legends

#### Supplementary Figure 1. Distribution of samples according to COVID-19 epidemiology in New 468 469 Caledonia. Absolute number of cases are shown in black on the left y axis, with Delta, Omicron BA.1 470 and Omicron BA.4/5 epidemic peaks. Absolute number of samples collected one month after the second dose (orange), three months after the second dose (green), one month after the third dose (blue) or 6 471 months after the third dose (violet) are shown on the right y axis. Inclusion periods are shown below the 472 473 graph. Supplementary Figure 2. ROC curve for the anti-S IgG threshold best discriminating samples 474 475 exhibiting Omicron neutralization capacity. 476 Supplementary Table 1. Participants' description at baseline (1 month after the 2<sup>nd</sup> or 3<sup>rd</sup> dose) 477 Supplementary Table 2. Comparison of immune characteristics after the 2<sup>nd</sup> or 3<sup>rd</sup> dose 478 **Supplementary Table 3.** Description of the participants followed up at month 1 and month 6 post-3<sup>rd</sup> 479 480 dose of vaccination (N=214) 481 Supplementary Table 4. Factors associated with the progression of anti-S IgG levels between one 482 and six months after immunization (linear regression) Supplementary Table 5. Factors associated with the loss of the ability to neutralize Omicron BA.1 483 484 and/or BA.4-5 between one and six months after immunization (logistic regression) Supplementary Table 6. Factors associated with the variation in the level of ADCC (CD16 485 activation) between one and six months after immunization (linear regression) 486 Supplementary Table 7. Description of participants sampled at 6 months after the 3<sup>rd</sup> dose of 487 488 immunization Supplementary Table 8. Factors associated with the levels of anti-S IgG six months after the 3<sup>rd</sup> dose 489 490 (linear regression) 491 Supplementary Table 9. Factors associated with the ability to neutralize Omicron BA.1 and/or BA.4-5 six months after the 3<sup>rd</sup> dose (logistic regression) 492

#### 493 References

- 4941.Tarantola, A., Horwood, P.F., Goarant, C., Bertrand, S., Merilles, O.E.A., Pedron, T., Klement-495Frutos, E., Sansonetti, P., Quintana-Murci, L. & Richard, V. Counting Oceanians of Non-496European, Non-Asian Descent (ONENA) in the South Pacific to Make Them Count in Global497Health. Trop Med Infect Dis 4(2019).
- Horwood, P.F., Tarantola, A., Goarant, C., Matsui, M., Klement, E., Umezaki, M., Navarro, S. &
   Greenhill, A.R. Health Challenges of the Pacific Region: Insights From History, Geography,
   Social Determinants, Genetics, and the Microbiome. *Frontiers in Immunology* **10**(2019).
- 5013.Burrage, R.L., Mills, K.J., Coyaso, H.C., Gronowski, C.K. & Godinet, M.T. Community Resilience502and Cultural Responses in Crisis: Lessons Learned from Pacific Islander Responses to the503COVID-19 Pandemic in the USA. J Racial Ethn Health Disparities 11, 560-573 (2024).
- Thomas, S.J., Moreira, E.D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez
   Marc, G., Polack, F.P., Zerbini, C., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19
   Vaccine through 6 Months. *New England Journal of Medicine* **385**, 1761-1773 (2021).
- 5075.ISEE-NC. Institut de la statistique et des études économiques Nouvelle-Calédonie,508Recensement. (2019).
- 5096.DASS-NC. Direction des Affaires Sanitaires et Sociales de Nouvelle-Calédonie, Tableau de bord510COVID-19. (2023).
- 7. Ochida, N., Dupont-Rouzeyrol, M., Moury, P.H., Demaneuf, T., Gourinat, A.C., Mabon, S.,
   Jouan, M., Cauchemez, S. & Mangeas, M. Evaluating the strategies to control SARS-CoV-2 Delta
   variant spread in New Caledonia, a zero-COVID country until September 2021. *IJID Reg* 8, 64 70 (2023).
- 5158.Secretariat of the Pacific Community, S. COVID-19 vaccination Dataset Pacific Data Hub.516(2023).
- Shalil, L., Leary, M., Rouphael, N., Ofotokun, I., Rebolledo, P.A. & Wiley, Z. Racial and Ethnic
   Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. *Vaccines (Basel)* **10**(2022).
- Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez
  Marc, G., Moreira, E.D., Zerbini, C., *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19
  Vaccine. *New England Journal of Medicine* 383, 2603-2615 (2020).
- Priddy, F.H., Williams, M., Carson, S., Lavender, B., Mathieson, J., Frampton, C., Moreland, N.J.,
  McGregor, R., Williams, G., Brewerton, M., *et al.* Immunogenicity of BNT162b2 COVID-19
  vaccine in New Zealand adults. *Vaccine* 40, 5050-5059 (2022).
- 526 12. Zhang, W., Kedzierski, L., Chua, B.Y., Mayo, M., Lonzi, C., Rigas, V., Middleton, B.F., McQuilten,
  527 H.A., Rowntree, L.C., Allen, L.F., *et al.* Robust and prototypical immune responses toward
  528 COVID-19 vaccine in First Nations peoples are impacted by comorbidities. *Nature Immunology*529 24, 966-978 (2023).
- Dufloo, J., Grzelak, L., Staropoli, I., Madec, Y., Tondeur, L., Anna, F., Pelleau, S., Wiedemann,
   A., Planchais, C., Buchrieser, J., *et al.* Asymptomatic and symptomatic SARS-CoV-2 infections
   elicit polyfunctional antibodies. *Cell Rep Med* 2, 100275 (2021).
- Yu, Y., Wang, M., Zhang, X., Li, S., Lu, Q., Zeng, H., Hou, H., Li, H., Zhang, M., Jiang, F., et al.
  Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. *Signal Transduction and Targeted Therapy* 6, 346 (2021).
- Reich, D., Green, R.E., Kircher, M., Krause, J., Patterson, N., Durand, E.Y., Viola, B., Briggs, A.W.,
   Stenzel, U., Johnson, P.L., *et al.* Genetic history of an archaic hominin group from Denisova
   Cave in Siberia. *Nature* 468, 1053-1060 (2010).
- 16. Choin, J., Mendoza-Revilla, J., Arauna, L.R., Cuadros-Espinoza, S., Cassar, O., Larena, M., Ko,
  A.M., Harmant, C., Laurent, R., Verdu, P., *et al.* Genomic insights into population history and
  biological adaptation in Oceania. *Nature* **592**, 583-589 (2021).

- 542 17. Scepanovic, P., Alanio, C., Hammer, C., Hodel, F., Bergstedt, J., Patin, E., Thorball, C.W.,
  543 Chaturvedi, N., Charbit, B., Abel, L., *et al.* Human genetic variants and age are the strongest
  544 predictors of humoral immune responses to common pathogens and vaccines. *Genome Med*545 **10**, 59 (2018).
- Bates, T.A., McBride, S.K., Leier, H.C., Guzman, G., Lyski, Z.L., Schoen, D., Winders, B., Lee, J.Y.,
  Lee, D.X., Messer, W.B., *et al.* Vaccination before or after SARS-CoV-2 infection leads to robust
  humoral response and antibodies that effectively neutralize variants. *Sci Immunol* 7, eabn8014
  (2022).
- Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z.,
  Issa, H., *et al.* Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity
  against the omicron variant and severe disease: a systematic review and meta-regression. *Lancet Infect Dis* 23, 556-567 (2023).
- 554 20. Crotty, S. Hybrid immunity. *Science* **372**, 1392-1393 (2021).
- Wei, J., Pouwels, K.B., Stoesser, N., Matthews, P.C., Diamond, I., Studley, R., Rourke, E., Cook,
  D., Bell, J.I., Newton, J.N., *et al.* Antibody responses and correlates of protection in the general
  population after two doses of the ChAdOx1 or BNT162b2 vaccines. *Nat Med* 28, 1072-1082
  (2022).
- Grzelak, L., Velay, A., Madec, Y., Gallais, F., Staropoli, I., Schmidt-Mutter, C., Wendling, M.-J.,
  Meyer, N., Planchais, C., Rey, D., et al. Sex Differences in the Evolution of Neutralizing
  Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. *The Journal of Infectious Diseases* 224, 983-988 (2021).
- 563 23. Klein, S.L. & Flanagan, K.L. Sex differences in immune responses. *Nature Reviews Immunology*564 16, 626-638 (2016).
- 565 24. Cook, I.F. Sexual dimorphism of humoral immunity with human vaccines. *Vaccine* 26, 3551566 3555 (2008).
- 56725.Bunders, M.J. & Altfeld, M. Implications of Sex Differences in Immunity for SARS-CoV-2568Pathogenesis and Design of Therapeutic Interventions. Immunity 53, 487-495 (2020).
- Palacios-Pedrero, M., Jansen, J.M., Blume, C., Stanislawski, N., Jonczyk, R., Molle, A.,
  Hernandez, M.G., Kaiser, F.K., Jung, K., Osterhaus, A., et al. Signs of immunosenescence
  correlate with poor outcome of mRNA COVID-19 vaccination in older adults. *Nat Aging* 2, 896905 (2022).
- 573 27. Kara, Z., Akçin, R., Demir, A.N., Dinç, H., Taşkın, H.E., Kocazeybek, B. & Yumuk, V.D. Antibody
  574 Response to SARS-CoV-2 Vaccines in People with Severe Obesity. *Obes Surg* 32, 2987-2993
  575 (2022).
- Bates, J.T., Farmer, A.P., Bierdeman, M.A., Ederer, D.R., Carney, L.S., Montgomery, D.D.,
  Lirette, S.T. & Marshall, G.D. IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2
  Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. *Vaccines (Basel)*10(2022).
- Crawford, K.H.D., Eguia, R., Dingens, A.S., Loes, A.N., Malone, K.D., Wolf, C.R., Chu, H.Y.,
  Tortorici, M.A., Veesler, D., Murphy, M., *et al.* Protocol and Reagents for Pseudotyping
  Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* 12, 513
  (2020).
- 30. Grzelak, L., Temmam, S., Planchais, C., Demeret, C., Tondeur, L., Huon, C., Guivel-Benhassine,
  F., Staropoli, I., Chazal, M., Dufloo, J., et al. A comparison of four serological assays for
  detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. *Sci Transl Med* 12(2020).

588

Figure 1



### Distribution of the 849 samples



Number of participants

# Figure 2



C. Neutralization capacity against SARS-CoV-2 variants



B. Magnitude of the humoral response across communities one month after immunization





